CHECKMATE PHARMACEUTICALS, INC.
BioSniper Score
4-factor signal
Market Cap
—
Cash Runway
16.8 mo
Lead Asset
cmp-001 (Phase 2)
Next Catalyst
—
CHECKMATE PHARMACEUTICALS, INC.: 2 pipeline candidates · Updated within the last hour.
Go deeper on CHECKMATE PHARMACEUTICALS, INC. with Spotter
Ask follow-up questions and run a full multi-agent deep dive on CMPI — live, with citations.
Score breakdown4-factor signal · derived from public data
16.8 months
D/E 0.22 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Key Financialsas of March 31, 2022
Cash
$39.5M
Quarterly Burn
$10.7M
Free Cash Flow
-$10.7M
Total Liabilities
$11.9M
Shareholders Equity
$55.0M
Current Ratio
5.20
Commercialization & Governance
Commercialization
- Status
- Clinical-stage
- Has Revenue
- No
Governance
- Board Size
- 7
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| cmp-001 | Phase 2 |
| vidutolimod | Phase 2 |
Frequently asked questions
What is CHECKMATE PHARMACEUTICALS, INC.'s lead drug candidate?
CHECKMATE PHARMACEUTICALS, INC.'s most advanced tracked candidate is cmp-001 (Phase 2) for Head and neck squamous cell carcinoma (HNSCC).
Who is the CEO of CHECKMATE PHARMACEUTICALS, INC.?
Barry Labinger is the chief executive officer of CHECKMATE PHARMACEUTICALS, INC. (CMPI).
What therapeutic areas does CHECKMATE PHARMACEUTICALS, INC. focus on?
CHECKMATE PHARMACEUTICALS, INC. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on CHECKMATE PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.